Dr. Myrga discusses techniques to leverage transperineal prostate biopsy benefits
“When we think about all the other office-based procedures we do, such as transrectal biopsies and vasectomies that are done in-clinic, I think that technology can play a big role in these," says Dr. Myrga.
In an interview with Urology Times, John Myrga, MD, explains the significance of findings from his recent study, "Patient Reported Outcomes after Transperineal vs. Transrectal Biopsy with Local Anesthesia: Advances in Pain Control and Areas for Improvement." These findings were presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Myrga is a urology resident at University of Pittsburgh Medical Center’s urology department.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
